Neuromyelitis optica: it is time to move one step further

Tarso Adoni

doi:10.1590/0004-282X20170005

Arquivos de Neuro-Psiquiatria, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(02): 79-80
DOI: 10.1590/0004-282X20170005

EDITORIAL

Neuromyelitis optica: it is time to move one step further

Neuromielite óptica: é hora de dar um passo adiante

Tarso Adoni

¹Hospital Sírio-Libanês, São Paulo SP, Brasil;

²Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Neurologia, São Paulo SP, Brasil.

References
1 Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2016;1366(1):20-39. http://doi.org/10.1111/nyas.12794
2 Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. http://doi.org/10.1212/WNL.20170005201700051729
3 Del Negro MC, Marinho PBC, Papais-Alvarenga RM. Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. Arq Neuropsiquiatr. 2017;75(2):81-6. http://doi.org/10.1590/0004-282X20160193
4 Pittock SJ, Lennon VA, Wingerchuk DM, Homburger HA, Lucchinetti CF, Weinshenker BG. The prevalence of non-organ-specific auto antibodies and NMO IgG in neuromyelitis optica (NMO) and related disorders. Neurology. 2006;66:A307.
5 Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler. 2014;20(3):331-7. http://doi.org/10.1177/1352458513495581
6 Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD. et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler. 2016;22(3):302-11. http://dx.doi.org/10.1177/1352458515591069
7 Lana-Peixoto MA, Talim LE, Faria-Campos AC, Campos SV, Rocha CF, Hanke LA et al. NMO-DBr: the Brazilian Neuromyelitis Optica Database System. Arq Neuropsiquiatr. 2011;69(4):687-92. http://dx.doi.org/10.1590/S0004-282X2011000500021
8 Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):14. http://doi.org/10.1186/1742-2094-9-14
9 Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303. http://doi.org/10.1111/cen3.12107
10 Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Haidar Jorge FM, Takahashi T et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-81. http://doi.org/10.1212/WNL.20170005201700050101
11 Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E et al. Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311. http://doi.org/10.1212/NXI.20170005201700050311